Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 9NETWORK 1INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cisplatin 15Paclitaxel 14Taxes 10Cyclophosphamide 9Carboplatin 9Gemcitabine 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Trastuzumab 5Radiotherapy 5Oxaliplatin 5Doxorubicin 5Docetaxel 5Cytarabine 5Capecitabine 5Brachytherapy 5fludarabine 4Rituximab 4Radiosurgery 4Fluorouracil 4Dexamethasone 4Watchful Waiting 3Radiotherapy, Intensity-Modulated 3Pemetrexed 3Nimorazole 3Lenalidomide 3Imatinib Mesylate 3Idarubicin 3Gene Expression Profiling 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NETWORK × nilotinib × Clear all
NCT04578847 2020-10-08

READIT

National Research Center for Hematology, Russia

Phase 2 Unknown
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡